167 related articles for article (PubMed ID: 15129905)
1. E-cadherin expression in invasive urothelial carcinoma.
Sun W; Herrera GA
Ann Diagn Pathol; 2004 Feb; 8(1):17-22. PubMed ID: 15129905
[TBL] [Abstract][Full Text] [Related]
2. E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma.
Sun W; Herrera GA
Hum Pathol; 2002 Oct; 33(10):996-1000. PubMed ID: 12395372
[TBL] [Abstract][Full Text] [Related]
3. CD 10 expression intensity in various grades and stages of urothelial carcinoma of urinary bladder.
Atique M; Abbasi MS; Jamal S; Khadim MT; Akhtar F; Jamal N
J Coll Physicians Surg Pak; 2014 May; 24(5):351-5. PubMed ID: 24848395
[TBL] [Abstract][Full Text] [Related]
4. Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway.
Fukushima H; Koga F; Kawakami S; Fujii Y; Yoshida S; Ratovitski E; Trink B; Kihara K
Cancer Res; 2009 Dec; 69(24):9263-70. PubMed ID: 19934319
[TBL] [Abstract][Full Text] [Related]
5. Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladder.
Keck B; Wach S; Kunath F; Bertz S; Taubert H; Lehmann J; Stöckle M; Wullich B; Hartmann A
Ann Surg Oncol; 2013 Jul; 20(7):2440-5. PubMed ID: 23108554
[TBL] [Abstract][Full Text] [Related]
6. E-cadherin cell-adhesion molecule expression as a diagnostic adjunct in urothelial cytology.
Ross JS; Cheung C; Sheehan C; del Rosario AD; Bui HX; Fisher HA
Diagn Cytopathol; 1996 Jun; 14(4):310-5. PubMed ID: 8725130
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma.
Lim MG; Adsay NV; Grignon DJ; Osunkoya AO
Mod Pathol; 2011 Feb; 24(2):241-7. PubMed ID: 20818341
[TBL] [Abstract][Full Text] [Related]
8. Fascin determination in urothelial carcinomas of the urinary bladder: a marker of invasiveness.
Karasavvidou F; Barbanis S; Pappa D; Moutzouris G; Tzortzis V; Melekos MD; Koukoulis G
Arch Pathol Lab Med; 2008 Dec; 132(12):1912-5. PubMed ID: 19061289
[TBL] [Abstract][Full Text] [Related]
9. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.
DeGraff DJ; Clark PE; Cates JM; Yamashita H; Robinson VL; Yu X; Smolkin ME; Chang SS; Cookson MS; Herrick MK; Shariat SF; Steinberg GD; Frierson HF; Wu XR; Theodorescu D; Matusik RJ
PLoS One; 2012; 7(5):e36669. PubMed ID: 22590586
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical determination of ETS-1 oncoprotein expression in urothelial carcinomas of the urinary bladder.
Sari A; Calli A; Gorgel SN; Altinboga AA; Kara C; Dincel C; Cakalagaoglu F
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):153-8. PubMed ID: 21623185
[TBL] [Abstract][Full Text] [Related]
11. IMP3 expression in urothelial carcinomas of the urinary bladder.
Ozdemir NO; Türk NS; Düzcan E
Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
[TBL] [Abstract][Full Text] [Related]
12. CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma.
Omran OM
J Environ Pathol Toxicol Oncol; 2012; 31(3):203-12. PubMed ID: 23339695
[TBL] [Abstract][Full Text] [Related]
13. Expression of classic cadherins type I in urothelial neoplastic progression.
Rieger-Christ KM; Cain JW; Braasch JW; Dugan JM; Silverman ML; Bouyounes B; Libertino JA; Summerhayes IC
Hum Pathol; 2001 Jan; 32(1):18-23. PubMed ID: 11172290
[TBL] [Abstract][Full Text] [Related]
14. E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder.
Ross JS; del Rosario AD; Figge HL; Sheehan C; Fisher HA; Bui HX
Hum Pathol; 1995 Sep; 26(9):940-4. PubMed ID: 7672793
[TBL] [Abstract][Full Text] [Related]
15. The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma.
Erdemir F; Ozcan F; Kilicaslan I; Parlaktas BS; Uluocak N; Gokce O
Int Urol Nephrol; 2007; 39(4):1031-7. PubMed ID: 17340210
[TBL] [Abstract][Full Text] [Related]
16. Histopathological and immunohistochemical study of papillary urothelial neoplasms of low malignant potential and grade associated with extensive invasive low-grade urothelial carcinoma.
Mai KT; Elmontaser G; Perkins DG; Yazdi HM; Stinson WA; Thijssen A
BJU Int; 2004 Sep; 94(4):544-7. PubMed ID: 15329109
[TBL] [Abstract][Full Text] [Related]
17. E-cadherin and p63 immunoexpression in dysplastic lesions and urothelial carcinomas of the bladder.
Stepan A; Mărgăritescu C; Simionescu C; Ciurea R
Rom J Morphol Embryol; 2009; 50(3):461-5. PubMed ID: 19690775
[TBL] [Abstract][Full Text] [Related]
18. Reduced E-cadherin and alpha-catenin expressions have no prognostic role in bladder carcinoma.
Koksal IT; Ates M; Danisman A; Sezer C; Ciftcioglu A; Karpuzoglu G; Sevuk M
Pathol Oncol Res; 2006; 12(1):13-9. PubMed ID: 16554911
[TBL] [Abstract][Full Text] [Related]
19. Decreased ezrin and paxillin expression in human urothelial bladder tumors correlate with tumor progression.
Athanasopoulou A; Aroukatos P; Nakas D; Repanti M; Papadaki H; Bravou V
Urol Oncol; 2013 Aug; 31(6):836-42. PubMed ID: 21868260
[TBL] [Abstract][Full Text] [Related]
20. E-cadherin÷CD44 immunophenotype in the epithelial-mesenchymal transition of bladder urothelial carcinomas.
Stepan AE; Pirici D; Bălăşoiu M; Novac MB; Drocaş AI; Ciurea RN; Stepan D; Gheonea DI; Simionescu CE
Rom J Morphol Embryol; 2015; 56(1):85-91. PubMed ID: 25826491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
